Literature DB >> 16337909

Silencing polyglutamine degeneration with RNAi.

Nancy M Bonini1, Albert R La Spada.   

Abstract

Nine dominantly inherited neurodegenerative diseases are caused by expansion of a CAG repeat encoding glutamine. An important development in the study of such "polyglutamine" diseases was the realization that merely shutting off expression of a disease-encoding transgene could arrest progression in animal models with significant disease pathology. Such studies opened the door to a powerful new therapeutic approach now being pioneered: silencing of the dominant disease allele by RNA-mediated interference (RNAi), for the arrest--and potential reversal--of the disease process.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16337909     DOI: 10.1016/j.neuron.2005.11.008

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  11 in total

1.  Dietary restriction suppresses proteotoxicity and enhances longevity by an hsf-1-dependent mechanism in Caenorhabditis elegans.

Authors:  Katherine A Steinkraus; Erica D Smith; Christina Davis; Daniel Carr; William R Pendergrass; George L Sutphin; Brian K Kennedy; Matt Kaeberlein
Journal:  Aging Cell       Date:  2008-03-10       Impact factor: 9.304

2.  Getting a handle on Huntington's disease: silencing neurodegeneration.

Authors:  Albert R La Spada
Journal:  Nat Med       Date:  2009-03       Impact factor: 53.440

3.  Full sequence of mutant huntingtin 3'-untranslated region and modulation of its gene regulatory activity by endogenous microRNA.

Authors:  Kyung-Hee Kim; Kawther Abu Elneel; Jun Wan Shin; Jae Whan Keum; David Seong; Seung Kwak; Ramee Lee; James F Gusella; Marcy E MacDonald; Ihn Sik Seong; Jong-Min Lee
Journal:  J Hum Genet       Date:  2019-07-11       Impact factor: 3.172

4.  Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice.

Authors:  Alexander Pfeifer; Sabina Eigenbrod; Saba Al-Khadra; Andreas Hofmann; Gerda Mitteregger; Markus Moser; Uwe Bertsch; Hans Kretzschmar
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

Review 5.  Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives.

Authors:  J J Magaña; L Velázquez-Pérez; B Cisneros
Journal:  Mol Neurobiol       Date:  2012-09-21       Impact factor: 5.590

6.  Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9.

Authors:  Jun Wan Shin; Kyung-Hee Kim; Michael J Chao; Ranjit S Atwal; Tammy Gillis; Marcy E MacDonald; James F Gusella; Jong-Min Lee
Journal:  Hum Mol Genet       Date:  2016-10-15       Impact factor: 6.150

7.  CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup.

Authors:  Simon C Warby; Alexandre Montpetit; Anna R Hayden; Jeffrey B Carroll; Stefanie L Butland; Henk Visscher; Jennifer A Collins; Alicia Semaka; Thomas J Hudson; Michael R Hayden
Journal:  Am J Hum Genet       Date:  2009-02-26       Impact factor: 11.025

8.  Caffeine extends life span, improves healthspan, and delays age-associated pathology in Caenorhabditis elegans.

Authors:  George L Sutphin; Emma Bishop; Melana E Yanos; Richard M Moller; Matt Kaeberlein
Journal:  Longev Healthspan       Date:  2012-12-01

Review 9.  The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution.

Authors:  Nico P Dantuma; Laura C Bott
Journal:  Front Mol Neurosci       Date:  2014-07-31       Impact factor: 5.639

10.  Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi.

Authors:  Yusuke Ohnishi; Yoshiko Tamura; Mariko Yoshida; Katsushi Tokunaga; Hirohiko Hohjoh
Journal:  PLoS One       Date:  2008-05-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.